Novartis Hits Spartalizumab Phase III Setback In Melanoma
IO MAPK Inhibitor Combination Hopes Dashed
Novartis’s attempts to enter the PD1 market by combining its investigational immunotherapy spartalizumab with its Tafinlar and Mekinist BRAF/MEK combination have come unstuck, leaving Roche to the field.
